AbbVie, Nxera ink licensing deal worth up to $1.5B for bowel disease therapy

AbbVie and Nxera signed a licensing deal worth up to $1.5 billion for a bowel disease therapy.

AbbVie and Nxera signed a licensing deal worth up to $1.5 billion for a bowel disease therapy.

话题：#AbbVie and Nxera sign $1.5B bowel disease licensing deal

墨子AI